Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Gastroenterology. 2011 Jul 7;141(5):1738–1748.e2. doi: 10.1053/j.gastro.2011.06.070

Figure 5. DARPP-32 promotes EGFR protein stability and tyrosine phosphorylation.

Figure 5

A) MKN-28 cells stably expressing DARPP-32 or empty vector were treated with EGF (100 ng/ml) for the indicated time points, and total EGFR protein levels were determined by Western blot analysis. Relative EGFR expression levels are presented, time=0 is shown as 1.0. B) Western blot analysis using lysates from MKN-28/DARPP-32 stable cells (left panel) or infected with adenoviral DARPP-32 (right panel), following treatment with gefitinib (25μM) or vehicle (DMSO) overnight. C) Western blot analysis as in (B), following lentiviral shRNA DARPP-32 knockdown in SNU-16 cells. D-F) Immunoprecipitation with anti-p-Tyr(102) antibody followed by Western blot analysis of EGFR protein in MKN-28/DARPP-32 stable cells, treated with EGF (100 ng/ml) for 1h (D) or following lentiviral shRNA DARPP-32 knockdown in SNU-16 cells and treatment with EGF (E) or gefitinib (25μM) overnight (F).